Eidos Therapeutics reports publication of AG10 trial in JACC
Eidos Therapeutics announced the publication of its Phase 2 clinical trial studying AG10 in subjects with symptomatic TTR amyloid cardiomyopathy in the Journal of the American College of Cardiology entitled "Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy". Eidos also presented subgroup analyses from the same Phase 2 clinical study in an oral presentation at this year's American College of Cardiology Scientific Sessions. Stephen Heitner, M.D., director of the hypertrophic cardiomyopathy clinic at the Oregon Health & Science University, presented these findings in an oral presentation entitled "AG10 Consistently Stabilizes Transthyretin to a High Level in Both Wild Type and Mutant Amyloid Cardiomyopathy: Responder Analyses From a Phase 2 Clinical Trial". "These data confirm the potential ability of AG10 to treat ATTR-CM, regardless of mutational status," said Jonathan Fox, MD, PhD, president and chief medical officer of Eidos. "The observed near-complete stabilization of TTR in all actively treated subjects and across the dosing interval provide clinical proof-of-concept for AG10 in both wild-type and mutant ATTR-CM. These Phase 2 results support further investigation of AG10 in the ongoing ATTRibute-CM Phase 3 study." The primary results from the Phase 2 study were presented at the 2018 American Heart Association Annual Meeting in Chicago, IL on November 10, 2018.